Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Understanding the Genetic and Hereditary Basis of Atherosclerosis

NCT00344292 · View on ClinicalTrials.gov ↗

Study Summary

Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible for the development of atherosclerosis.

Study Locations (4)

California

  • Cedars-Sinai Health System — Los Angeles

Louisiana

  • Louisiana State University — New Orleans

Texas

  • The University of Texas — Houston

Washington

  • University of Washington — Seattle

Trial Details

FieldValue
Enrollment Target 2,763 participants
Start Date 2006-03
Est. Completion 2012-02

Sponsor

Wake Forest University Health Sciences

1,061 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00344292

The ClinicalTrials.gov registry entry for NCT00344292 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,763 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,061 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00344292 reports 4 study locations spanning 4 distinct geographic areas — top geographies include California, Louisiana, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00344292 about?

NCT00344292 is a clinical study titled "Understanding the Genetic and Hereditary Basis of Atherosclerosis". Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible...

What is the current status of trial NCT00344292?

This trial is currently completed. The enrollment target is 2,763 participants. The study started on 2006-03. Estimated completion is 2012-02.

What conditions does trial NCT00344292 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00344292?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,061 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00344292 being conducted?

This trial has 4 study locations across California, Louisiana, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial